SCHEMBL154175

SCHEMBL154175

CCCCN(CCCC)C(=O)O.[Nd]

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.56
CA1 P00915 3/20 0.56
CA9 Q16790 3/20 0.56
MMP1 P03956 1/20 0.52
MMP2 P08253 1/20 0.52
MMP3 P08254 1/20 0.52
MMP8 P22894 1/20 0.52
ALDH1A1 P00352 3/20 0.44
ALDH2 P05091 1/20 0.44
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
CA2 P00918 1/20 0.41
AKR1B1 P15121 1/20 0.40
HDAC1 Q13547 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
GPR84 Q9NQS5 6/20 0.39
PPARG P37231 6/20 0.39
PPARD Q03181 6/20 0.39
PPARA Q07869 6/20 0.39
HDAC11 Q96DB2 5/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL751749 0.97 CA12 (0.58) CA12CA1CA9MMP1MMP2
Bromide SCHEMBL11745071 0.95 CA12 (0.56) CA12CA1CA9MMP1MMP2
SCHEMBL673692 0.95 CA12 (0.56) CA12CA1CA9MMP1MMP2
Hydrochloric Acid SCHEMBL5827201 0.95 CA12 (0.56) CA12CA1CA9MMP1MMP2
SCHEMBL640838 0.95 CA12 (0.56) CA12CA1CA9MMP1MMP2
SCHEMBL2884564 0.95 CA12 (0.56) CA12CA1CA9MMP1MMP2
SCHEMBL8773488 0.95 CA12 (0.56) CA12CA1CA9MMP1MMP2
SCHEMBL673393 0.95 CA12 (0.56) CA12CA1CA9MMP1MMP2
Hydrogen Sulfide SCHEMBL28206766 0.95 CA12 (0.56) CA12CA1CA9MMP1MMP2
SCHEMBL1405537 0.95 CA12 (0.56) CA12CA1CA9MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 486 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3969490-B1 MODIFIED HIGH-CIS POLYBUTADIENE POLYMER, RELATED METHODS AND TIRE COMPONENTS BRIDGESTONE CORP (JP) 2026-03-25 EP disclosed
US-12565546-B2 Imine group-containing novel compound, modified conjugated diene-based polymer including same, method for preparing the polymer, and rubber composition including the polymer LG CHEM, LTD. (KR) 2026-03-03 US disclosed
US-20250389555-A1 MODIFIED HIGH-CIS POLYBUTADIENE POLYMER, RELATED METHODS AND RUBBER COMPOSITIONS BRIDGESTONE AMERICAS TIRE OPERATIONS, LLC (US) 2025-12-25 US disclosed
EP-4653477-A1 CONJUGATED DIENE-BASED POLYMER AND RUBBER COMPOSITION LG CHEM, LTD. (KR) 2025-11-26 EP disclosed
US-12410263-B2 Modified high-Cis polybutadiene polymer, related methods and rubber compositions BRIDGESTONE AMERICAS TIRE OPERATIONS, LLC (US) 2025-09-09 US disclosed
EP-4032921-B1 METHOD FOR PREPARING MODIFIED CONJUGATED DIENE-BASED POLYMER LG CHEMICAL LTD (KR) 2025-08-27 EP disclosed
US-12371516-B2 Aged lanthanide-based catalyst systems and their use in the preparation of cis-1,4-polydienes BRIDGESTONE CORPORATION (JP) 2025-07-29 US disclosed
US-12264232-B2 Modified high-cis polybutadiene polymer, related methods and tire components BRIDGESTONE CORPORATION (JP) 2025-04-01 US disclosed
US-20250066516-A1 HYDROGENATED POLYBUTADIENE POLYMERS AND RUBBER COMPOSITIONS INCORPORATING SAME BRIDGESTONE CORPORATION (JP) 2025-02-27 US disclosed
US-12209149-B2 Continuous preparation system of conjugated diene-based polymer LG CHEM, LTD. (KR) 2025-01-28 US disclosed
WO-2005061563-A1 BULK POLYMERIZATION PROCESS FOR PRODUCING POLYDIENES BRIDGESTONE CORPORATION (JP) 2005-07-07 WO disclosed
US-20050131174-A1 Bulk polymerization process for producing polydienes BRIDGESTONE CORP. 2005-06-16 US disclosed
US-6897270-B2 Continuous process for the production of conjugated diene polymers having narrow molecular weight distribution and products therefrom BRIDGESTONE CORPORATION (JP) 2005-05-24 US disclosed
US-20050038215-A1 Lanthanide-based catalyst composition for producing cis-1,4-polydienes BRIDGESTONE CORPORATION (JP) 2005-02-17 US disclosed
US-20040116638-A1 Continuous process for the production of conjugated diene polymers having narrow molecular weight distribution and products therefrom BRIDGESTONE CORPORATION (JP) 2004-06-17 US disclosed
CN-1494556-A Continuous process for production of conjugated diene polymers having narrow molecular weight distribution and products therefrom ������������ʽ���� 2004-05-05 CN disclosed
US-6699813-B2 COMPOSITION THAT IS COMBINATION OF OR REACTION PRODUCT OF LANTHANIDE COMPOUND, ALKYLATING AGENT, NICKEL-CONTAINING COMPOUND, AND OPTIONALLY HALOGEN-CONTAINING COMPOUND THAT INCLUDES ONE OR MORE LABILE HALOGEN ATOMS BRIDGESTONE CORPORATION (JP) 2004-03-02 US disclosed
EP-1370593-A1 CONTINUOUS PROCESS FOR THE PRODUCTION OF CONJUGATED DIENE POLYMERS HAVING NARROW MOLECULAR WEIGHT DISTRIBUTION AND PRODUCTS THEREFROM Bridgestone Corporation (JP) 2003-12-17 EP disclosed
US-20030176276-A1 Lanthanide-based catalyst composition for the manufacture of polydienes BRIDGESTONE CORPORATION (JP) 2003-09-18 US disclosed
WO-2002068484-A1 CONTINUOUS PROCESS FOR THE PRODUCTION OF CONJUGATED DIENE POLYMERS HAVING NARROW MOLECULAR WEIGHT DISTRIBUTION AND PRODUCTS THEREFROM BRIDGESTONE CORPORATION (JP) 2002-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12565546-B2 Imine group-containing novel compound, modified conjugated diene-based polymer including same, method for preparing the polymer, and rubber composition including the polymer CARM1, RIF1, UFM1 CA12 4569/4885CA1 4752/4885CA9 4596/4885
US-20250389555-A1 MODIFIED HIGH-CIS POLYBUTADIENE POLYMER, RELATED METHODS AND RUBBER COMPOSITIONS MALT1, INO80C, RTCB CA12 997/4885CA1 678/4885CA9 1041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.